ArticleInfectious diseases of poverty2025
Safety and effectiveness of triple-drug therapy with ivermectin, diethylcarbamazine, and albendazole in reducing lymphatic filariasis prevalence and clearing circulating filarial antigens in Mombasa, Kenya.
Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global Epidemiology of Vector-Borne Parasitic Diseases: Burden, Trends, Disparities, and Forecasts (1990-2036).Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn 2018, Kenya introduced triple-drug therapy with ivermectin, diethylcarbamazine, albendazole (IDA) through mass drug administration (MDA) to accelerate the elimination of lymphatic filariasis (LF). This community-based surveillance study assessed the safety and effectiveness of IDA-MDA in reducing LF-antigenemia prevalence and circulating filarial antigens (CFA) clearance among LF infected individuals.
methodsA total of 8928 residents in Mombasa, Kenya, were screened for CFA using the Filarial Test Strip: 3464 were screened in 2018 and 5464 in 2021 after two annual IDA-MDA rounds. CFA-positive individuals in 2021 were re-tested at two and four months of post-MDA for CFA-clearance rates. Adverse events (AEs) associated with IDA-MDA were monitored via door-to-door visits on days 1, 2, and 7 post-MDA to document the incidence, type and risk factors. Efficacy outcomes included post-MDA LF-antigenemia prevalence reduction after two rounds of annual MDA and CFA clearance rate. Chi-square test compared proportions, and logistic regression analysis identified AE predictors.
resultsLF antigenemia prevalence significantly decreased from 1.39% (n = 48) in 2018 to 0.66% (n = 36) in 2021 [P < 0.001; 95% confidence interval (CI) for difference in proportions: 0.003-0.012]. CFA clearance rates were 63.2% (12/19, 95% CI: 41.0-80.1%) at 2 months and 68.4% (13/19, 95% CI: 46.0-86.6%) at 4 months post-MDA. Among 53 CFA-positive individuals monitored, the cumulative 7-day AE incidence was 37.7% (95% CI: 25.6-51.7), higher than the general population's 27.3% (95% CI: 26.4-28.2). Common AEs included nausea (11.3%), diarrhea (11.3%), abdominal pain (7.6%), and headache (5.7%). Risk factors for AEs included age, overweight status, concomitant medication use, chronic illness, and fasting before MDA.
conclusionsTriple therapy with IDA is safe and well-tolerated, with some mild-to-moderate and transient adverse events among LF-infected individuals. The high incidence of AEs highlights the need for safety monitoring during MDA. The significant reductions in LF antigenemia prevalence and high CFA clearance rates underscore IDA's effectiveness in reducing LF transmission, positioning it as a key strategy for eliminating LF as a public health problem by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.